If you are not happy with the results below please do another search
Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis (MG), the company announced Friday in its full-year 2022 financial report.
Keytruda, could be on its way to snagging another indication as a first-line therapy for endometrial cancer after the company announced positive Phase III results Friday.
CanSino Biologics CEO Yu Xuefeng said on Friday he was confident his company’s experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech.
Gilead Sciences Inc. said on Friday the U.S. Food and Drug Administration had greenlighted expanded use of Trodelvy to treat the most common type of breast cancer, marking the third approval for the drug.
The U.S. Food and Drug Administration has warned against using an India-made eye drop that has been linked to the outbreak of a drug-resistant bacteria leading to adverse events in at least 55 patients including infections, blindness and one death.
India will spend $79.6 million on strengthening its drug regulatory system, the health minister said on Friday, after the World Health Organization raised concerns about domestically produced cough syrups being linked to the death of 89 children in two countries.
Regeneron Pharmaceuticals Inc. reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.
With strong industry relationships, Spicker further amplifies Leaderboard’s branding and naming expertise in the biopharma space.
Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, the company revealed Thursday in its 2022 full-year financial report.
BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German pharmaceutical firm said on Thursday.
